| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 15 May 2024 | 8 May 2024 |
| Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2024 inter alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31 2024 and to evaluate various options or proposals for raising funds through any of the permissible modes subject to the receipt of necessary approvals. The Board of Directors of the Company at its meeting held today i.e. May 15 2024, has inter alia consider and approve the: 8. Re-appointment of M/s M. K. Kulshrestha & Associates, Cost Accountants as the Cost Auditors of the Company for the Financial Year 2024-25. 9. Re-appointment of M/s Dayal & Maur, Company Secretaries as the Secretarial Auditors of the Company for the Financial Year 2024-25. Raising of Funds by issuance of such number of Equity Shares having face value of Re. 1 each of the Company (Equity Shares) and/or other eligible securities or any combination thereof, or an aggregate amount not exceeding Rs. 7,500 Crore or an equivalent amount thereof by way of issuance of Equity/Equity linked securities under Qualified Institutional Placement or through issuance of FCCBs, ADRs/ GDRs/ Debt Securities or through any permissible mode. The Board of Directors of the Company at its meeting held today i.e. May 15, 2024 has inter alia consider and approved the increase in Authorized Share Capital of the Company. Outcome of Board Meeting held today i.e. May 15, 2024 Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations). (As Per BSE Announcement Dated on 15/05/2024) | ||
| Board Meeting | 2 Apr 2024 | 2 Apr 2024 |
| The Board of Directors of the Company at its meeting held today i.e. April 2, 2024, has inter-alia, considered and approved the following: 1. Slump sale of the Over the Counter (OTC) . The Board of Directors of the Company at its meeting held today i.e. April 2, 2024 has inter-alia, considered and approved the Incorporation of a wholly owned subsidiary by the name Mankind Consumer Products Private Limited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs. Read less.. | ||
| Board Meeting | 31 Jan 2024 | 16 Jan 2024 |
| Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday January 31 2024 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended on December 31 2023. Further in continuation of our earlier letter dated December 27 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till February 02 2024. The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. Outcome of Board Meeting held today i.e. January 31, 2024 (As Per BSE Announcement dated on 31.01.2024) | ||
| Board Meeting | 31 Oct 2023 | 11 Oct 2023 |
| Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Tuesday October 31 2023 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30 2023. Further in continuation of our earlier letter dated September 27 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till November 02 2023. The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. Outcome of Board Meeting held today i.e. October 31, 2023 Announcement under Regulation 30 (LODR) - Amalgamation / Merger (As Per BSE Announcement dated on 31.10.2023) Newspaper Publication of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2023 (As Per BSE Announcement Dated on 01/11/2023) Submission of application for reclassification from Promoter & Promoter Group category to Public Category under Regulation 31A of the SEBI (LODR) Regulations, 2015 (As Per BSE Announcement Dated on 27/11/2023) | ||
| Board Meeting | 2 Aug 2023 | 18 Jul 2023 |
| Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday 2nd August 2023 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on 30th June 2023. Further in continuation of our earlier letter dated 29th June 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed upto 48 hours after the declaration of unaudited standalone and consolidated financial results of the Company for the quarter ended on 30th June 2023. Mankind Pharma Limited has informed BSE about Board Meeting to be held on 02 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Outcome of Board Meeting as per letter attached. The Board at its meeting held on 02nd August, 2023 has inter alia approved the following: 1. Re-appointment of Mr. Ramesh Juneja as Chairman and Whole Time Director. 2. Re-appointment of Mr. Rajeev Juneja as Vice Chairman and Managing Director. 3. Re-appointment of Mr. Sheetal Arora as Whole-time Director and Chief Executive Officer. 4. Re-designation of Mr. Suresh Raju Penmetsa as Chief Risk Officer and Vice President EHS. 5. Re-appointment of M/s Dayal & Maur, Company Secretaries as the Secretarial Auditor of the Company for the FY 2023-24. 6. Ratification of Mankind Employee Stock Option Plan 2022. 7. Ratification of grant of employee stock option to the employees of subsidiary company(ies)/Group Company/ Associate Companies. Item no. 1, 2, 3, 6 and 7 are subject to approval of the members of the Company. (As per BSE Announcement Dated on 02/08/2023) | ||
The Delhi-based startup has signed in-licensing arrangements with Novartis for the heart failure treatment Neptaz.
Mankind Pharma's stock increased by more than 4% after the block deal. Mankind Pharma's shares were trading at ₹2,169 on the NSE at 09.23 am.
Here are some of the stocks that may see significant price movement today: ONGC, Wipro, Reliance, RVNL, Mahindra & Mahindra, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
